Eli Lilly Faces Enhanced Oral Weight-Loss Competition as Novo Nordisk Secures First FDA Approval

Novo Nordisk secured U.S. FDA approval for its oral Wegovy on December 23, positioning it as the first oral weight-loss GLP-1 drug on the market. This development presents a strategic challenge and competitive pressure for Eli Lilly, whose oral candidate, orforglipron, is anticipated for approval in the first half of 2026.

Despite this, Eli Lilly maintains a strong market position with its injectable blockbusters Mounjaro and Zepbound. Analyst sentiment remains positive, with a consensus "Moderate Buy" rating and a price target of approximately $1,155.